Intra‐aortic balloon pump in cardiogenic shock: A propensity score matching analysis

Abstract Objective To assess the impact of intra‐aortic balloon pumps (IABP) on patients with cardiogenic shock in an intensive care unit setting. Background IABP counterpulsation is a widely used mechanical circulatory support device, but its performance has been questioned. However, current evidence of IABP use in cardiogenic shock is very limited (mainly from the IABP‐SHOCK II trial), which was restricted to cardiogenic shock complicating acute myocardial infarction. Methods This was a retrospective, real‐world, cohort study based on the Medical Information Mart for Intensive Care III database. Adult patients with a diagnosis of cardiogenic shock were eligible. Results A total of 1028 patients with cardiogenic shock were assessed, including 384 patients who received IABP and 644 patients who did not. The in‐hospital mortality was significantly lower in patients who received IABP (adjusted odds ratio: 0.75, 95% confidence interval: 0.62–0.91, p = 0.009). Analysis of secondary endpoints found that the use of IABP was associated with a significantly lower risk of 1‐year mortality. After propensity score matching, the in‐hospital mortality remained significantly lower in the IABP group (28.10% vs. 37.59%, p = 0.018). Conclusions In the current cohort, IABP treatment was associated with a lower risk of in‐hospital mortality in patients with cardiogenic shock. Due to the complexity of pathophysiology in cardiogenic shock and the discrepancies in current evidence, our results should be validated through further studies in the future.